Study finds nearly one-third of COPD and asthma patients misuse inhalers
CHICAGO A study presented at CHEST 2007, the 73rd annual international scientific assembly of the American College of Chest Physicians showed that 32.1 percent of patients with asthma or chronic obstructive pulmonary disease made at least one error while using a dry powder inhaler.
“The frequent misuse of dry powder inhalers can lead to the inappropriate dosage of medication, which can result in increased morbidity and mortality for patients,” said study author Siegfried Wieshammer of Klinikum Offenburg in Offenburg, Germany. “Our results suggest that inhaler type, age, severity of lung obstruction and prior training can determine the risk of inhalation errors. These factors should be considered before prescribing an inhaler for a patient.”
In patients that had not received instruction on how to use the inhaler, the error rate was 52.6 percent compared to 23.1 percent of people who were trained. Patients who were at least 60-years-old have an error rate of 41.6 percent, while people under 60 only had an error rate of 20 percent.
Pharma, biotech companies in line of wildfires
SAN DIEGO With the wildfires still blazing in areas across San Diego, such pharma and biotech companies as Pfizer are preparing for closures and even evacuations of some of their facilities, according to drugresearcher.com.
Pfizer’s La Jolla research and development site is a 33.5-acre campus, with facilities covering more than 1 million square feet, including Pfizer’s vaccines research and The Pfizer Incubator, a new facility where the company is financing life science start-ups. The HIV drug Viracept is produced at the site, as well as new treatments for cancer and diseases of the eye.
Across San Diego County, there are more than 500 life science companies employing more than 36,000 people, according to industry association Biocom. The companies range from small biotechs to some of the biggest names in drug development, such as Johnson & Johnson, Bristol-Myers Squibb, Amgen, Biogen Idec, Genentech and Pfizer. Between them, they generate more than $23 million for the economy every day.
Pharmacy OneSource ranks in Deloitte’s top 100
BELLEVUE, Wash. Pharmacy OneSource has been ranked number 84 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. The company grew 2011 percent in fiscal revenue from 2002-2006, which was the time period used to measure each company’s ranking.
“We enjoy our strong relationship with pharmacy professionals and the opportunity it brings to stay intimate with their needs,” said Keith Streckenbach, chief strategy officer. “This knowledge, combined with excellent hires, has catalyzed our growth.”
Pharmacy OneSource was also ranked sixth on the Washington State Technology Fast 50, which ranks the 50 fastest growing technology firms in Washington State.